ARAVIVE (ARAV) Competitors $0.04 0.00 (0.00%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsSustainabilityTrendsBuy This Stock ARAV vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying ARAVIVE stock or one of its competitors? The main competitors of ARAVIVE include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. ARAVIVE vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity ARAVIVE (NASDAQ:ARAV) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. Do insiders and institutionals believe in ARAV or ATNFW? 35.8% of ARAVIVE shares are held by institutional investors. 60.4% of ARAVIVE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor ARAV or ATNFW? In the previous week, ARAVIVE's average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment ARAVIVE Neutral 180 Life Sciences Neutral Is ARAV or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets ARAVIVEN/A N/A N/A 180 Life Sciences N/A N/A N/A Which has preferable valuation and earnings, ARAV or ATNFW? 180 Life Sciences has lower revenue, but higher earnings than ARAVIVE. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARAVIVE$9.14M0.32-$76.32MN/AN/A180 Life SciencesN/AN/AN/AN/AN/A SummaryARAVIVE beats 180 Life Sciences on 3 of the 3 factors compared between the two stocks. Get ARAVIVE News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARAV vs. The Competition Export to ExcelMetricARAVIVEMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E RatioN/A21.5627.5220.22Price / Sales0.32281.76421.02118.64Price / CashN/A42.7336.8958.07Price / BookN/A7.518.045.67Net Income-$76.32M-$55.05M$3.18B$249.13M7 Day PerformanceN/A4.61%2.90%3.28%1 Month PerformanceN/A4.72%3.70%5.55%1 Year PerformanceN/A5.92%36.15%21.12% ARAVIVE Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeATNFW180 Life SciencesN/A$0.01-4.8%N/A-19.8%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/A-80.9%$0.00N/A0.002AIMDWAinosN/A$0.15flatN/AN/A$0.00$106.21K0.0040Gap DownALVOWAlvotechN/A$1.70+13.3%N/A-47.3%$0.00$585.60M0.004Positive NewsACABWAtlantic Coastal Acquisition Corp. IIN/A$0.02-0.5%N/AN/A$0.00N/A0.0015BFRIWBiofronteraN/A$0.11+16.9%N/AN/A$0.00$38.00M0.0070Positive NewsGap UpBTMDWbioteN/A$0.01-31.5%N/A-97.9%$0.00$199.38M0.00N/AGap UpBCTXWBriaCell TherapeuticsN/A$0.08+0.1%N/A-70.4%$0.00N/A0.008CELUWCelularityN/A$0.04flatN/A+100.0%$0.00$54.22M0.00220Positive NewsGap Down Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors CELUW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARAV) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARAVIVE, INC Please log in to your account or sign up in order to add this asset to your watchlist. Share ARAVIVE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARAV Stock Alerts